logo
episode-header-image
Nov 2023
1h 32m

Freely Filtered 064: Freely Filtered wit...

NephJC Team
About this episode

The Filtrate:

Joel Topf

Swapnil Hiremath

Sophia Ambruso

AC Gomez

Josh Waitzman

Jennie Lin

Nayan Arora

The Curbsiders

Matt F. Watto (@DoctorWatto)

Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz)

With Special Guest:

JD Foster (@KidneyVet)

Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital Signs

Michelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX Trial

Editor:

Joel Topf

Show Notes:

Lily toxicity in the cat (PubMed)

Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)

Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)

Nephrology in Veterinary Medicine (Kidney 360)

Star Wars Society of San Antonio (FaceBook)

These Vital Signs (Amazon)

Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)

The pearl not the patient (PubMed)

Late Braking and High Impact Clinical Trial press release

MENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)

KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)

Sophie’s number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)

Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).

Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)

AC Gomez’s Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org)

Josh’s Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)

Nayan’s Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine)

The Freely Filtered simultaneous release (NephJC)

Freely Filtered is now a verb.

Swap’s Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)

Joel’s Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)

Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)

Michelle’s Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)

Up next
Jun 9
NephJC RoboPod Episode 1: The Stamp Act Tac v MMF in Pediatric Nephrotic Syndrome
One of NephJC signature moves has been to adapt new technologies and communication techniques to delivering state of the art nephrology education. Podcasts, Visual Abstracts, Tweetorials. NephJC has been on the front of these waves. Clearly one of the most exciting and controvers ... Show More
19m 27s
May 13
FF 80 KDIGO ADPKD Guidelines
The FiltrateJoel TopfAC GomezSophia AmbrusoNayan AroraSpecial Guest Charles Edelstein, MD, PhD Professor, Medicine-Renal Med Diseases/HypertensionExtra-Special GuestMichelle Rheault, MD Professor of Pediatrics, University of MinnesotaEditing bySimon and Joel TopfThe Kidney Connec ... Show More
1h 18m
Apr 22
FF 79 REGENCY, Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
The Filtered Fragments (OG Filtrate)Joel TopfJennie LinSwapnil HiremathSpecial Guest Brad Rovin GN God and second author from The Ohio StateKoyal Jain GN Specialist from UNCAlfred Kim Rheumatologist from Washington UniversityEditing bySimon Topf and Nayan AroraThe Kidney Connecti ... Show More
1h 42m
Recommended Episodes
Jul 2019
Best of Juni
Cholesterinmessung - Semaglutid - KM-Nephropathie Studientelegramm 79-2019-1/3 Titel der Studie: Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm Autoren: Mora et al. Journal: ... Show More
6m 28s
Nov 2022
Podcast 833: NS vs LR
Contributor: Travis Barlock, MD Educational Pearls: Normal Saline (NS) contains 154 mEq of both Sodium (Na) and Chloride (Cl),  and has a pH of 5.5 Normal Na and Cl in adult humans are about 140 mEq/L and 103 mEq/L. respectively   Excess negative charge resulting from hyperchlore ... Show More
5m 16s
Dec 2022
Dec 2, 2022 This Week in Cardiology Podcast
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. ... Show More
24 m
Oct 2023
Podcast 873: Intravesical Tranexamic Acid for Gross Hematuria
Contributor: Aaron Lessen MD Educational Pearls: Tranexamic acid (TXA) is a common medication to achieve hemostasis in a variety of conditions Patients visiting the ED for gross hematuria (between March 2022 and September 2022) were treated with intravesical TXA 1 g tranexamic ac ... Show More
2m 23s
Mar 2022
REBOOT #145 Hepatorenal Syndrome
Tackle the complex pathophysiology, diagnosis, and management of hepatorenal syndrome in this Curbsiders classic from #NephMadness 2019 featuring @kidney_boy Joel Topf, HRS expert Juan Carlos Velez (@veleznephhepato), and self-proclaimed most-handsome-nephrologist Bill Whittier ( ... Show More
1h 8m
Sep 2021
Diabetes Core Update SGLT2s and Diabetic Kidney Disease
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca. For more ... Show More
36m 4s
Sep 2023
S2 Episode 4: Chronic Kidney Disease: FSGS, Genetic Testing, and APOL1
Join Drs Matthew Sparks and Kirk Campbell as they dive into the murky waters of focal segmental glomerular sclerosis. How do you diagnose? How do you treat? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/vi ... Show More
27m 55s
Jun 2023
June 16 This Week in Cardiology
AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week's podcast This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I ... Show More
27m 59s
Aug 2022
S1 Episode 1: Chronic Kidney Disease and SGLT2 Inhibitors: Usage, Monitoring, and Possible Side Effects
Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/vie ... Show More
24m 28s
Oct 2022
Oct 21, 2022 This Week in Cardiology Podcast
The ERASE AF ablation trial, left bundle pacing, finerenone, and perceptions of cardiology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://ww ... Show More
26m 37s